NuCana plc
NCNA · XNASCIK 1709626fmd_1W79EM5G8A878VH2FA011QSEBMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 29 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 8 | 18 | 17 | 20 | 26 | 37 | 36 | 25 | 18 | 13 |
| Operating income | (8) | (26) | (19) | (27) | (36) | (48) | (39) | (33) | (23) | (20) |
| Interest expense | – | 2 | – | – | – | – | – | 0 | 0 | 13 |
| Income before taxes | (8) | (25) | (18) | (26) | (36) | (48) | (38) | (32) | (22) | (31) |
| Income tax expense | (2) | (2) | (4) | (4) | (5) | (7) | (6) | (4) | (3) | (1) |
| Net income from continuing operations | (6) | (23) | (14) | (21) | (31) | (41) | (32) | (28) | (19) | (29) |
| Net income | (6) | (23) | (14) | (21) | (31) | (41) | (32) | (28) | (19) | (29) |